We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Metabolic disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Primary prevention of common chronic disease is a major public health goal. Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. The clinical onset of type 1 diabetes is preceded by a phase where the child is well but has multiple beta-cell auto-antibodies in their blood against insulin-producing beta cells,which are present in the pancreas. Neonates and infants who are at increased risk of developing multiple beta-cell auto-antibodies and type 1 diabetes can now be identified using genetic markers. This provides an opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.
The objective of this study is to determine the percentage of children with genetic markers putting them at increased risk of developing type 1 diabetes, and to offer the opportunity for these children to be enrolled into phase II b primary prevention trials.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
• Mother is unwilling or unable to give written informed consent to participate in the study • Mother is unable to understand written or verbal English which would preclude them from understanding the study • Baby’s blood spot card is not processed at either the Royal Victoria Infirmary (Newcastle)or Addenbrooke’s Hospital (Cambridge) • Mother has received sperm and/or egg donation for the pregnancy and is unaware of the donor’s type 1 diabetes status
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Steve
Robson
s.c.robson@ncl.ac.uk
The study is sponsored by THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST and funded by THE LEONA AND HARRY B HELMSLEY FOUNDATION INC .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 50294
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
